Oncternal Therapeutics Gets FDA Fast-Track on Prostate Cancer Treatment
By Dean Seal Oncternal Therapeutics said regulators have granted its fast-track designation for ONCT-534, a treatment for patients with relapsed or...
James Breitmeyer Drug Administration San Diego Based Executive James Breitmeyer Dean Seal Article Normal
Source: marketwatch.com